Search results
Prof Mariya Moosajee at Moorfields Eye Hospital has asked us to share the message below about the clinical trial she is running. This trial is for a treatment that targets a particular section of the USH2A gene.
Do you know your facts from your fiction? Host a quiz for Retina UK and raise vital funds for our ground-breaking work.
Join Lauren as she chats with Paula McGrath, Deputy CEO of Retina UK, about the 2025 Sight Loss Survey
Stem cells are a special type of cell, which under the right conditions can be encouraged to grow into any other type of cell in the body, including retinal cells (rods, cones and retinal pigment epithelial cells).
There are about 125 million rod and cone cells within the retina that act as the eye's light receptors.
Growth factors are substances that promote the health and function of cells and tissues in the body.
Our partnerships are mutually beneficial. For Retina UK this means we can fund more research and offer support on a local level, while our partners can achieve corporate social responsibility objectives whilst making a tangible impact.
You may have heard that a cell-based treatment approach (sometimes referred to as a “stem cell treatment”), developed by a company called ReNeuron, is being tested in a clinical trial at Oxford Eye Hospital and other centres in the US and Europe.
Whether you are looking for practical information or emotional support, online, by phone or face-to-face, we’re here to help.
Thursday 15 May 2025, 7.00pm - 8.00pm - via Zoom - Come and join us for our latest meeting where we will be joined by our guest speakers and new sponsors, EMVI - A Mobile Visual Assistant Designed by and for the Visually Impaired.
